Last update 09 Dec 2024
Imidafenacin
Last update 09 Dec 2024
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms Imidafenacin (JAN/INN), KRP 197, KRP-197 + [9] |
Mechanism M1 receptor antagonists(Muscarinic acetylcholine receptor M1 antagonists), M3 receptor antagonists(Muscarinic acetylcholine receptor M3 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (18 Apr 2007), |
Regulation- |
Login to view timeline
Structure
Molecular FormulaC20H21N3O |
InChIKeySQKXYSGRELMAAU-UHFFFAOYSA-N |
CAS Registry170105-16-5 |
Related
47
Clinical Trials associated with Imidafenacin咪达那新片在中国健康受试者中的单中心、随机、开放、双周期、双交叉空腹及餐后状态下的生物等效性试验
[Translation] A single-center, randomized, open-label, two-period, double-crossover bioequivalence study of imidacin tablets in Chinese healthy subjects under fasting and fed conditions
A randomized, open-label, two-formulation, two-period, crossover study of the bioequivalence of a single oral dose of Imidafenacin tablets in fasted and fed healthy Chinese subjects
咪达那新片（0.1mg）在中国健康人群中空腹和餐后状态下单次给药的人体生物等效性临床试验
[Translation] A human bioequivalence clinical trial of imidacin tablets (0.1 mg) in Chinese healthy subjects after single administration in fasting and fed state
100 Clinical Results associated with Imidafenacin
Login to view more data
100 Translational Medicine associated with Imidafenacin
Login to view more data
100 Patents (Medical) associated with Imidafenacin
Login to view more data
106
Literatures (Medical) associated with Imidafenacin19 Apr 2024ACS chemical biology
Characterization of Chemical Interactions between Clinical Drugs and the Oral Bacterium, Corynebacterium matruchotii, via Bioactivity-HiTES
Article
Author: Kim, Jonghwan ; Kim, Chung Sub ; Kim, Ki Hyun ; Lee, Seoung Rak ; Song, Jeongwon ; Lee, Gyu Sung ; Lee, Bum Soo ; Park, Sehwan ; Lee, Da Yeong
In the field of natural product research, the rediscovery of already-known compounds is one of the significant issues hindering new drug development. Recently, an innovative approach called bioactivity-HiTES has been developed to overcome this limitation, and several new bioactive metabolites have been successfully characterized by this method. In this study, we applied bioactivity-HiTES to Corynebacterium matruchotii, the human oral bacterium, with 3120 clinical drugs as potential elicitors. As a result, we identified two cryptic metabolites, methylindole-3-acetate (MIAA) and indole-3-acetic acid (IAA), elicited by imidafenacin, a urinary antispasmodic drug approved by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). MIAA showed weak antibacterial activity against a pulmonary disease-causing Mycobacterium conceptionense with an IC50 value of 185.7 μM. Unexpectedly, we also found that C. matruchotii metabolized fludarabine phosphate, a USFDA-approved anticancer drug, to 2-fluoroadenine which displayed moderate antibacterial activity against both Bacillus subtilis and Escherichia coli, with IC50 values of 8.9 and 20.1 μM, respectively. Finally, acelarin, a prodrug of the anticancer drug gemcitabine, was found to exhibit unreported antibacterial activity against B. subtilis with an IC50 value of 33.6 μM through the bioactivity-HiTES method as well. These results indicate that bioactivity-HiTES can also be applied to discover biotransformed products in addition to finding cryptic metabolites in microbes.
01 Jan 2024Investigative and Clinical Urology
Efficacy and safety evaluation of imidafenacin administered twice daily for continency recovery following radical prostatectomy in prostate cancer patients: Prospective open-label case-controlled randomized trial
Article
Author: Kim, Soodong ; Goh, Hyeok Jun ; Lee, Kwang Min ; Lee, Jun Hee ; Choi, Dong Won ; Lee, Kisoo
PURPOSE:
This study aims to prospectively analyze the effects of anticholinergic therapy using imidafenacin on detrusor overactivity occurring after robot-assisted radical prostatectomy (RARP).
MATERIALS AND METHODS:
Patients were followed-up at outpatient visits 2-4 weeks post-surgery (visit 2) to confirm the presence of urinary incontinence. Those confirmed with urinary incontinence were randomly assigned in a 1:1 ratio to the anticholinergic medication group (imidafenacin 0.1 mg twice daily) or the control group. Patients were followed-up at 1, 3, and 6 months post-surgery for observational assessments, including the International Prostate Symptom Score (IPSS) and Overactive Bladder Symptom Score (OABSS).
RESULTS:
A total of 49 patients (25 in the treatment group and 24 in the control group) were randomized for the study. There were no differences observed between the groups in terms of age, comorbidities, prostate size, or pathological staging. According to the IPSS questionnaire results, there was no statistically significant difference between the medication and control groups (p=0.161). However, when comparing storage and voiding symptoms separately, there was a statistically significant improvement in storage symptom scores (p=0.012). OABSS also revealed statistically significant improvement in symptoms from 3 months post-surgery (p=0.005), which persisted until 6 months post-surgery (IPSS storage: p=0.023, OABSS: p=0.013).
CONCLUSIONS:
In the case of urinary incontinence that occurs after RARP, even if the function of the intrinsic sphincter is sufficiently preserved, if urinary incontinence persists due to changes in the bladder, pharmacological therapy using imidafenacin can be beneficial in managing urinary incontinence.
01 May 2023Lower urinary tract symptoms
Efficacy and safety of vibegron compared with mirabegron for overactive bladder: A systematic review and network meta‐analysis
Review
Author: He, Wenjuan ; Zhang, Yuqian ; Sun, Qian ; Liu, Xiuju ; Huang, Guangliang ; Tian, Yunfei
Abstract:
Objectives:
The aim of this study was to indirectly compare the efficacy and safety of mirabegron and vibegron in patients with overactive bladder.
Methods:
A systematic search was performed on Pubmed, Web of Science, Embase, and the Cochrane Central Register of Controlled Trials databases to identify studies from the date of database inception to January 1, 2022. All randomized controlled trials comparing mirabegron or vibegron with tolterodine, imidafenacin, or placebo were eligible. One reviewer extracted data, and a second reviewer checked. Included trials were assessed for similarity, and networks were developed using Stata 16.0 software. Mean differences for continuous variables and odds ratios for dichotomous variables together with their 95% confidence intervals (CIs) were used to rank treatments and compare the differences, respectively.
Results:
A total of 11 randomized controlled trials and 10 806 patients were included. For each outcome, results for all licensed treatment doses were included. Both vibegron and mirabegron were more efficacious than placebo at reducing the frequency of micturition, incontinence, urgency, urgency incontinence, and nocturia. Vibegron was more efficacious than mirabegron in reducing mean voided volume/micturition (95% CI [5.15, 14.98]). Safety outcomes for vibegron and mirabegron were similar to those in the placebo group, except for mirabegron, which had a higher risk of nasopharyngitis and cardiovascular adverse events than placebo.
Conclusions:
Both drugs seem to be comparable and well tolerated, particularly as direct comparisons are not available. However, vibegron may be more effective than mirabegron in reducing mean voided volume.
100 Deals associated with Imidafenacin
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D06273 | Imidafenacin |
R&D Status
Approved
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Urinary Bladder, Overactive | JP | 18 Apr 2007 | |
| Urinary Bladder, Overactive | JP | 18 Apr 2007 |
Developing
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Pollakisuria | NDA/BLA | RU | 30 Jan 2022 | |
| Urinary Incontinence, Urge | Phase 1 | CN | 17 Jun 2015 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
NCT03575702 (Pubmed) Manual  | Phase 3 | 300 | rjolkxmmus(qmkosfiwgf) = qcixaipqhn ixpgcasjuk (bgzvigvomx, 2.2) View more | Non-inferior | 01 Jun 2019 | ||
rjolkxmmus(qmkosfiwgf) = pittbylhsu ixpgcasjuk (bgzvigvomx, 1.8) View more | |||||||
Phase 3 | 300 | (Uritos®) | jarursvrjl(frttqbmlqi) = gtpxujhvcr jsdbkfmppk (wiwgxvvmoo, zugnmxbdmz - ouwfpdwvgx) View more | - | 21 May 2019 | ||
(Urotol®) | jarursvrjl(frttqbmlqi) = opsnosyzdu jsdbkfmppk (wiwgxvvmoo, clfolcqdow - hetullnbze) View more | ||||||
Phase 4 | 649 | (Mirabegron + Solifenacin) | yzuovzvlol(ydymbwguxi) = iawhxnlvwf lgzzovzqpf (onragwobzv, jvuhkmwuch - raginsniac) View more | - | 24 Dec 2018 | ||
(Mirabegron + Propiverine) | yzuovzvlol(ydymbwguxi) = okxwjgvhvb lgzzovzqpf (onragwobzv, vuvcxghyec - wzbsbklwxm) View more | ||||||
Not Applicable | 308 | dvfsabdewr(ddemlkkfls) = sgvzotfpei lisfcvfmwg (zgjxvbrzxx, 1.47 - 2.74) View more | Positive | 01 Oct 2013 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free